fbpx

Weekly Top News – IBD – October 14, 2019

October 14, 2019

ozanimod (RPC1063) / Celgene
Ozanimod clinical trial estimate: Data from P3 TRUE NORTH trial (NCT02435992) for moderate-to-severe ulcerative colitis in mid-2020 (Guggenheim) – Oct 8, 2019 – A subscription to Thomson ONE is required to gain full access to report 68001013; Page no: 2; REPORT TITLE: “Highlights from our autoImmune/immunology KOL series Part 3: Emerging treatment landscape in Crohn’s Disease and ulcerative colitis”; AUTHOR: Fernandez, Seamus, et al; DATE: 09/24/2019

 

filgotinib (GLPG0634) / Gilead
Filgotinib clinical trial estimate: Topline data from P2b/3 SELECTION1 trial (NCT02914522) for ulcerative colitis in H1 2020 (Cantor Fitzgerald) – Oct 10, 2019 – A subscription to Thomson ONE is required to gain full access to report 68016498; Page no: 1; REPORT TITLE: “Cantor conference class of 2019: Top questions, catalysts, and who is most likely to….”; AUTHOR: Research Department; DATE: 09/26/2019

 

Myoconda (clarithromycin/clofazimine/rifabutin) / RedHill
RedHill Biopharma Announces Full Results from Positive MAP US Phase 3 Study and Supportive Top-Line Results from MAP US2 Open-Label Extension Study with RHB-104 in Crohn’s Disease (GlobeNewswire, RedHill Biopharma Ltd.) – Oct 11, 2019 – P3, N=330; MAPUS (NCT01951326); P3, N=331; MAPUS2 (NCT03009396); Sponsor: NCT01951326; “RedHill Biopharma Ltd…announced full Week 52 results for all subjects in the previously announced positive Phase 3 randomized, controlled study of RHB-104 in Crohn’s disease (the ‘MAP US study’) and supportive top-line results from the open-label extension Phase 3 study (the ‘MAP US2 study’). The full Week 52 results of blinded treatment in the MAP US Phase 3 study….continued to meet its primary endpoint…”

 

Xeljanz (tofacitinib) / Pfizer
Xeljanz US sales projection: $2.7B in 2024 (Infinata) – Oct 12, 2019 – A subscription to Thomson ONE is required to gain full access to report 68065169; Page no: 14; REPORT TITLE: “Pfizer, Inc. – Company report”; AUTHOR: Infinata, et al; DATE: 10/07/2019

 

Stelara (ustekinumab) / J&J
Stelara patent expiry: September 2023 in US (Edison Investment Research) – Oct 11, 2019 – A subscription to Thomson ONE is required to gain full access to report 68038761; Page no: 4; REPORT TITLE: “Formycon – H119 results – FYB201 FDA filing imminent”; AUTHOR: Savin, John, et al; DATE: 10/02/2019

 

Humira (adalimumab) / Eisai, AbbVie; Remicade (infliximab) / Mitsubishi Tanabe, J&J
HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn’s disease (Gastroenterology) – Oct 7, 2019 – P=NA, N=1,240; “We performed a genome-wide association study to identify variants associated with time to development of anti-drug antibodies in…patients with Crohn’s disease starting infliximab or adalimumab therapy…In an observational study, we found a genome-wide significant association between HLA-DQA1*05 and the development of antibodies against anti-TNF agents.”

 

Otezla (apremilast) / Amgen
Otezla sales projection: $4B in 2027 (Oppenheimer) – Oct 8, 2019 – A subscription to Thomson ONE is required to gain full access to report 68004961; Page no: 1; REPORT TITLE: “Amgen Inc- Key takeaways from meeting with management”; AUTHOR: Research Department; DATE: 09/24/2019

No Comments

Post a Comment

Comment
Name
Email
Website